Synamedia sold its Video Network arm. Can its new CEO make the smaller company grow faster?
The leadership handover puts an internal architect of Synamedia’s cloud, streaming and monetisation strategy in charge as the Permira-backed company narrows its operating model.
Can Alleva Intelligence turn compliance software into its strongest AI advantage?
Alleva is combining clinical documentation, compliance management, workforce knowledge and executive analytics under Alleva Intelligence, escalating competition to become the central operating platform for behavioral health providers.
Why Bayer moved its U.S. Roundup and glyphosate operations into Ruveon LLC
Find out how Bayer’s Ruveon launch could reshape U.S. glyphosate pricing, Roundup strategy, farmer costs and legal risk.
Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two
Vertex Pharmaceuticals wins FDA approval to expand Casgevy to children as young as two, reshaping sickle cell treatment economics.
ITG lands a $312m IPO, but the $16 price reveals what investors would not pay
ITG priced its Nasdaq initial public offering below the proposed range, raising $312.2 million as investors weighed broadband growth against debt, weaker margins and customer concentration.
BridgeBio Pharma weighs $1bn KKR, Sixth Street preferred equity deal as launch costs rise
BridgeBio Pharma may be preparing its balance sheet for three potential product launches, but the value of a $1 billion preferred equity deal will depend heavily on its undisclosed dividend, conversion and redemption terms.
Lime IPO prices at $25, but a $115 million debt bill shapes the real investment case
Uber-backed Lime has secured a roughly $174 million Nasdaq offering at a $25 share price, but debt repayment, regulatory dependence and seasonal cash flow will shape the investment case after LIME begins trading.
Can potravitug justify Ipsen’s €700m-plus Memo Therapeutics acquisition?
Ipsen is acquiring Memo Therapeutics to secure potravitug, a clinical-stage antibody targeting a serious kidney transplant complication. The structure limits Ipsen’s upfront exposure while placing the larger valuation behind clinical, regulatory and commercial success.
Mitsubishi Electric’s JAXA grant looks small for earnings but large for space autonomy
Discover how Mitsubishi Electric's ¥5.25 billion JAXA grant could advance Japan's satellite autonomy and influence the outlook for 6503 shares. Read it now.
Netsmart doubles Bengaluru office as healthcare AI and engineering footprint expands
Netsmart has doubled its Bengaluru office to 60,000 square feet, turning India into a larger engineering, artificial intelligence and quality-assurance hub. The expansion could accelerate healthcare software development, but its commercial importance will depend on hiring quality, global integration and measurable product outcomes.